| 1 |
28561722 | Therapeutic Bone-Modifying Agents in the Nonmetastatic Breast Cancer Setting: The Controversy and a Value Assessment. | 2017 |
1 |
| 2 |
22073949 | Bone mineral density, pathological fractures and bisphosphonate therapy in prostate cancer patients on androgen deprivation therapy. | 2011 Oct |
1 |
| 3 |
20456336 | Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer. | 2010 Nov |
1 |
| 4 |
19432128 | [Effectiveness of bisphosphonate administration during Gn-RH agonist therapy for endometriosis]. | 2009 May |
3 |
| 5 |
18161132 | [Effectiveness of bisphosphonate administration for prevention of osteopenia during Gn-RH agonist therapy of endometriosis]. | 2007 Nov 28 |
1 |
| 6 |
16730272 | Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update. | 2006 Apr |
1 |
| 7 |
17062721 | Treatment-related osteoporosis in men with prostate cancer. | 2006 Oct 15 |
1 |
| 8 |
15775084 | [Bisphosphonate for GnRH therapy]. | 2003 Feb |
2 |